Article in Radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors.
Ryan KohlbrennerFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.ORCID 0000-0002-2479-0698
Xiao WuFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.
Hao G NguyenFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.
Matthew R CooperbergFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.ORCID 0000-0003-4339-6685
Tushar ChakravartyFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.ORCID 0000-0002-8778-7998
Peter R CarrollFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.
Thomas A HopeFrom the Departments of Radiology and Biomedical Imaging (R.K., X.W., T.A.H.), Urology (H.G.N., M.R.C., P.R.C.), and Pathology (T.C.), University of California San Francisco, 505 Parnassus Ave, M361, San Francisco, CA 94143.ORCID 0000-0002-2228-5823
Funding
MELT: Modulation of PSMA Expression for Lutetium TherapyR01CA235741 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS A · 2019 to 2025
$3.2M
Qualification and Harmonization of PET/MRI for Cancer Clinical TrialsR01CA212148 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOPE, THOMAS, LAFOREST, RICHARD ANDRE · 2017 to 2022
$2.7M
NCI NIH HHS R01 CA212148NCI NIH HHS R01 CA235741
6 · The paper itself
Abstract
Background Intravenous prostate-specific membrane antigen (PSMA)-targeted radioligand therapy improves survival in men with metastatic castration-resistant prostate cancer. Yet, the impact of selective prostatic arterial administration on primary tumor uptake is unclear. Purpose To compare gallium 68 (
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmacokinetic Comparison of Selective Prostatic Arterial and Intravenous PSMA PET/CT Radioligand Infusions in Primary Prostatic Adenocarcinoma. · full record | OpenQuestion